靶向人VEGF165的SiRNA慢病毒的构建和鉴定(3)
 |
| 第1页 |
参见附件(1982KB，3页)。
[4]王西樵,陆树良,毛志刚,等. 增生性瘢痕中血管内皮细胞生物学功能的研究[J].中华烧伤杂志,2007,23 (3) 3:219-221.
[5]Zhang GY,Yi CG,Li X,et al. Inhibition of vascular endothelial growth factor expression in keloid fibroblasts by vector-mediated vascular endothelial growth factor shRNA: a therapeutic potential strategy for keloid[J].Arch Dermatol Res,2008,300(4):177-184.
[6]Senger DR,Galli SJ,Dvorak AM,et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.[J]. Science,1983,219(4587): 983-985.
[7]Otrock ZK,Makarem JA,Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review[J]. Blood Cells Mol Dis,2007,38(3):258-268.
[8]Neufeld G,Cohen T,Gengrinovitch S,et al. Vascular endothelial growth factor (VEGF) and its receptors[J].FASEB J,1999,13(1):9-22.
[9]Zhao J,Pettigrew GJ,Thomas J,et al.Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo[J].Basic Res Cardiol,2002,97(5):348-358.
[10]Bauer G, Dao MA, Case SS, et al.In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors[J].Mol Ther,2008,16(7):1308-1315.
[收稿日期]2011-04-15 [修回日期]2011-06-20
编辑/张惠娟
您现在查看是摘要介绍页，详见PDF附件(1982KB，3页)。